Current Oncology (Nov 2021)

Acute Care Use by Breast Cancer Patients on Adjuvant Chemotherapy in Alberta: Demonstrating the Importance of Measurement to Improving Quality

  • Che Hsuan David Wu,
  • May Lynn Quan,
  • Shiying Kong,
  • Yuan Xu,
  • Jeffrey Q. Cao,
  • Sasha Lupichuk,
  • Lisa Barbera

DOI
https://doi.org/10.3390/curroncol28060375
Journal volume & issue
Vol. 28, no. 6
pp. 4420 – 4431

Abstract

Read online

Breast cancer patients receiving adjuvant chemotherapy are at increased risk of acute care use. The incidence of emergency department (ED) visits and hospitalizations (H) have been characterized in other provinces but never in Alberta. We conducted a retrospective population-based cohort study using administrative data of women with stage I-III breast cancer receiving adjuvant chemotherapy. Rates of ED and H use in the 180 days following chemotherapy initiation were determined, and logistic regression was performed to identify risk factors. We found that 47% of women receiving adjuvant chemotherapy experienced ED or H, which compared favourably to other provinces. However, Alberta had the highest rate of febrile neutropenia-related ED visits, and among the highest chemotherapy-related ED visits. The incidence of acute care use increased over time, and there were significant institutional differences despite operating under a single provincial healthcare system. Our study demonstrates the need for systematic measurement and the importance of quality improvement programs to address this gap.

Keywords